Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen as a screening test. The Austrian experience

A Reissigl1, G Bartsch

  • 1Department of Urology, University of Innsbruck, Austria.

The Urologic Clinics of North America
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trend analysis and regional tumor incidence in Germany for testicular cancer between 2003 and 2014.

Andrology·2019
Same author

[Unexpected differential diagnosis of urachal cancer].

Der Urologe. Ausg. A·2018
Same author

[Urolithiasis 2016 : Reliable, effective and low radiation exposure].

Der Urologe. Ausg. A·2016
Same author

[Patient blood management: Current state of the literature].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2015
Same author

[Cystectomy in the elderly patient].

Der Urologe. Ausg. A·2013
Same author

Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells.

British journal of cancer·2012

Prostate-Specific Antigen (PSA) screening significantly boosts early prostate cancer detection, identifying more curable and aggressive tumors. Advanced methods like age-specific ranges and free-to-total PSA ratios enhance diagnostic accuracy.

Area of Science:

  • Urology
  • Oncology
  • Medical Diagnostics

Background:

  • Prostate cancer screening is crucial for early detection and improved treatment outcomes.
  • Prostate-Specific Antigen (PSA) is a key biomarker in prostate cancer diagnostics.

Purpose of the Study:

  • To evaluate the effectiveness of PSA-based screening in detecting prostate cancer.
  • To assess the role of PSA in identifying organ-confined and aggressive tumors.
  • To explore the utility of advanced PSA metrics (age-specific ranges, free/total ratio) in screening.

Main Methods:

  • Analysis of detection rates and tumor characteristics in PSA-screened populations.
  • Evaluation of incidental tumors (A1 grade III/A2 vs. A1 grade I/II) in relation to PSA screening.
  • Assessment of age-specific PSA reference ranges and free-to-total PSA ratio calculations.

Related Experiment Videos

Main Results:

  • PSA screening substantially increases the detection rate of prostate cancer and organ-confined tumors.
  • A high percentage (96%) of detected tumors exhibit features of aggressive cancer.
  • PSA screening reduces detection of insignificant tumors while increasing detection of significant ones.
  • Age-specific ranges and free-to-total PSA ratios improve screening specificity and aid in biopsy decisions.

Conclusions:

  • PSA is the most effective tool for early prostate cancer detection.
  • PSA-based screening, enhanced by advanced metrics, is clinically valuable for early diagnosis.
  • Continued PSA screening is recommended for early detection of prostate cancer.